uniQure N.V. – NASDAQ:QURE

uniQure N.V. stock price today

$15.28
-2.22
-12.69%
Financial Health
0
1
2
3
4
5
6
7
8
9

uniQure N.V. stock price monthly change

+100.69%
month

uniQure N.V. stock price quarterly change

+100.69%
quarter

uniQure N.V. stock price yearly change

+157.35%
year

uniQure N.V. key metrics

Market Cap
816.44M
Enterprise value
792.33M
P/E
-7.16
EV/Sales
7.44
EV/EBITDA
-7.33
Price/Sales
8.24
Price/Book
1.84
PEG ratio
0.05
EPS
-6.20
Revenue
19.00M
EBITDA
-244.25M
Income
-296.86M
Revenue Q/Q
59.34%
Revenue Y/Y
-82.72%
Profit margin
-119.07%
Oper. margin
-134.44%
Gross margin
95.18%
EBIT margin
-134.44%
EBITDA margin
-1285.37%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

uniQure N.V. stock price history

uniQure N.V. stock forecast

uniQure N.V. financial statements

uniQure N.V. (NASDAQ:QURE): Profit margin
Jun 2023 2.42M -68.47M -2827.17%
Sep 2023 1.40M -89.57M -6366.1%
Dec 2023 6.68M -73.20M -1094.42%
Mar 2024 8.48M -65.61M -773.34%
uniQure N.V. (NASDAQ:QURE): Analyst Estimates
Sep 2025 30.84M -36.43M -118.13%
Oct 2025 24.38M -39.39M -161.59%
Dec 2025 13.89M -47.40M -341.15%
Mar 2026 6.50M -52.86M -812.21%
  • Analysts Price target

  • Financials & Ratios estimates

uniQure N.V. (NASDAQ:QURE): Debt to assets
Jun 2023 942769000 589.44M 62.52%
Sep 2023 871550000 602.76M 69.16%
Dec 2023 831689000 624.01M 75.03%
Mar 2024 770050000 623.29M 80.94%
uniQure N.V. (NASDAQ:QURE): Cash Flow
Jun 2023 -56.99M 45.83M 370.13M
Sep 2023 38.91M -314.06M -7.59M
Dec 2023 -49.54M 59.56M 46K
Mar 2024 -60.57M 63.98M 0

uniQure N.V. alternative data

uniQure N.V. (NASDAQ:QURE): Employee count
Aug 2023 501
Sep 2023 501
Oct 2023 501
Nov 2023 501
Dec 2023 501
Jan 2024 501
Feb 2024 501
Mar 2024 480
Apr 2024 480
May 2024 480
Jun 2024 480
Jul 2024 480

uniQure N.V. other data

35.13% -45.08%
of QURE is owned by hedge funds
16.37M -21.20M
shares is hold by hedge funds

uniQure N.V. (NASDAQ:QURE): Insider trades (number of shares)
Period Buy Sel
Feb 2024 0 53265
Jun 2024 0 29851
Dec 2024 0 105214
Transaction Date Insider Security Shares Price per share Total value Source
Option
KAPUSTA MATTHEW C director, officer.. Ordinary Shares 100,000 $14.71 $1,471,000
Sale
KAPUSTA MATTHEW C director, officer.. Ordinary Shares 100,000 $15.03 $1,503,000
Option
KAPUSTA MATTHEW C director, officer.. Stock Option (Right to Buy) 100,000 $14.71 $1,471,000
Sale
KAPUSTA MATTHEW C director, officer.. Ordinary Shares 3,418 $7.63 $26,079
Sale
KLEMT CHRISTIAN officer: Chief Fi.. Ordinary Shares 1,796 $7.55 $13,560
Sale
ABI-SAAB WALID officer: Chief Medical Officer
Ordinary Shares 1,447 $4.36 $6,309
Sale
CALOZ PIERRE officer: Chief Operating Officer
Ordinary Shares 2,936 $4.81 $14,122
Sale
KLEMT CHRISTIAN officer: Chief Fi.. Ordinary Shares 1,611 $4.8 $7,733
Sale
JACQUES RACHELLE SUZANNE director
Ordinary Shares 2,221 $5.14 $11,416
Sale
POTTS JEANNETTE officer: Chief Legal Officer
Ordinary Shares 4,781 $4.98 $23,809
Sunday, 15 December 2024
fool.com
Wednesday, 11 December 2024
zacks.com
Tuesday, 10 December 2024
globenewswire.com
Friday, 29 November 2024
zacks.com
Thursday, 28 November 2024
zacks.com
Thursday, 21 November 2024
globenewswire.com
Friday, 8 November 2024
zacks.com
Tuesday, 5 November 2024
zacks.com
globenewswire.com
Tuesday, 29 October 2024
zacks.com
Tuesday, 15 October 2024
globenewswire.com
Monday, 23 September 2024
globenewswire.com
Thursday, 15 August 2024
globenewswire.com
Tuesday, 6 August 2024
seekingalpha.com
Thursday, 1 August 2024
zacks.com
globenewswire.com
Friday, 26 July 2024
zacks.com
Tuesday, 23 July 2024
globenewswire.com
Friday, 12 July 2024
forbes.com
Wednesday, 10 July 2024
zacks.com
zacks.com
zacks.com
Tuesday, 9 July 2024
seekingalpha.com
zacks.com
investorplace.com
globenewswire.com
Monday, 1 July 2024
prnewswire.com
globenewswire.com
Monday, 3 June 2024
globenewswire.com
Tuesday, 7 May 2024
globenewswire.com
  • What's the price of uniQure N.V. stock today?

    One share of uniQure N.V. stock can currently be purchased for approximately $15.28.

  • When is uniQure N.V.'s next earnings date?

    Unfortunately, uniQure N.V.'s (QURE) next earnings date is currently unknown.

  • Does uniQure N.V. pay dividends?

    No, uniQure N.V. does not pay dividends.

  • How much money does uniQure N.V. make?

    uniQure N.V. has a market capitalization of 816.44M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 85.12% to 15.84M US dollars.

  • What is uniQure N.V.'s stock symbol?

    uniQure N.V. is traded on the NASDAQ under the ticker symbol "QURE".

  • What is uniQure N.V.'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of uniQure N.V.?

    Shares of uniQure N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are uniQure N.V.'s key executives?

    uniQure N.V.'s management team includes the following people:

    • Mr. Matthew Craig Kapusta Chief Executive Officer & Executive Director(age: 53, pay: $965,480)
    • Dr. Alexander E. Kuta Ph.D. Executive Vice President of Quality & Regulatory(age: 65, pay: $652,580)
    • Dr. Ricardo Dolmetsch Ph.D. Pres of R&D(age: 56, pay: $626,150)
    • Mr. Christian Klemt Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site(age: 52, pay: $392,600)
  • How many employees does uniQure N.V. have?

    As Jul 2024, uniQure N.V. employs 480 workers.

  • When uniQure N.V. went public?

    uniQure N.V. is publicly traded company for more then 11 years since IPO on 5 Feb 2014.

  • What is uniQure N.V.'s official website?

    The official website for uniQure N.V. is uniqure.com.

  • How can i contact uniQure N.V.?

    uniQure N.V. can be reached via phone at +31 20 240 6000.

uniQure N.V. company profile:

uniQure N.V.

uniqure.com
Exchange:

NASDAQ

Full time employees:

480

Industry:

Biotechnology

Sector:

Healthcare

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Paasheuvelweg 25a
Amsterdam, 1105 BP

CIK: 0001590560
ISIN: NL0010696654
CUSIP: N90064101